Why Still in Neurosurgical Ward After Tumor Craniotomy?
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05288088 |
Recruitment Status :
Recruiting
First Posted : March 18, 2022
Last Update Posted : August 17, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Surgery--Complications Brain Tumor | Diagnostic Test: No intervention |
Study Type : | Observational |
Estimated Enrollment : | 200 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Factors Associated With Prolonged In-hospital Stay After Elective Tumor Craniotomy. |
Actual Study Start Date : | June 12, 2022 |
Estimated Primary Completion Date : | February 28, 2023 |
Estimated Study Completion Date : | December 31, 2024 |
Group/Cohort | Intervention/treatment |
---|---|
Tumor craniotomy patients
Patients undergoing elective brain tumor craniotomy
|
Diagnostic Test: No intervention
This is an observational study |
- Hospital length of stay [ Time Frame: Patients are followed for a maximum of 6 months. ]Length of stay is defined as the length of inpatient stay, based on number of nights spent at the neurosurgical ward, calculated from the day of surgery to the day of discharge from the neurosurgical ward.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Patients scheduled for elective brain tumor craniotomy
Exclusion Criteria:
- Stereotactic biopsy, pituitary surgery and laser interstitial thermal therapy (LITT)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05288088
Contact: Martin K Sørensen, Phd | +4535457009 | martin.kryspin.soerensen.01@regionh.dk | |
Contact: Alexandra Vassilieva | +4535457230 | alexandra.vassilieva@regionh.dk |
Denmark | |
Department of Neuroanesthesiology, Rigshospitalet | Recruiting |
Copenhagen, Denmark | |
Contact: Alexandra Vassilieva, MD +4526525373 alexandra.vassilieva@regionh.dk |
Principal Investigator: | Martin K Sørensen, PhD | Department of Neuroanesthesiology, Rigshospitalet |
Responsible Party: | Alexandra Vassilieva, Medical doctor, PhD-student, Rigshospitalet, Denmark |
ClinicalTrials.gov Identifier: | NCT05288088 |
Other Study ID Numbers: |
NSwardcraniotomy |
First Posted: | March 18, 2022 Key Record Dates |
Last Update Posted: | August 17, 2022 |
Last Verified: | August 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Brain Neoplasms Central Nervous System Neoplasms Nervous System Neoplasms Neoplasms by Site |
Neoplasms Brain Diseases Central Nervous System Diseases Nervous System Diseases |